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Background
Literature on treatment of Raynaud's phenomenon (RP)
in the paediatric age group is scarce, and practice varies.
We completed a retrospective analysis of patients with RP
treated by paediatric rheumatologists at Royal Liverpool
Children's Hospital to assess clinical response to medical
treatments including calcium channel blockers (nifed-
ipine and amlodipine) and Glyceryl trinitrate (GTN)
patches.
Methods
Clinic letters and case notes were reviewed. RP was graded
as mild, moderate or severe according to frequency and
severity of symptoms. Response to treatment was assessed
by reduction in symptoms without significant adverse
effects.
Results
A total of 45 patients were included in the study of which
42 (32 with primary and 10 with secondary Raynaud's)
had sufficient data available for analysis. 14 patients did
not receive any medical intervention. 28 patients received
one or more medical treatments sequentially over time.
GTN patches were used in 18 patients of whom 9 (50%)
demonstrated a good response. Three more patients await
assessment. Six patients failed to improve, or had adverse
effects. Nifedipine was used in 11 patients of whom 4
(36%) showed a good response. Amlodipine was used in
12 patients of whom 3 (25%) showed a good response.
Conclusion
No one treatment option is uniformly efficacious in
patients with Raynaud's. GTN patches seem to be effective
without significant adverse effects. Amlodipine and nifed-
ipine were useful in smaller percentages of patients. Clin-
ical response was similar in patients with primary and
secondary Raynaud's. Responses according to severity of
disease are discussed.
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